Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an orally administered drug to disrupt prostate cancer cells’ metabolism and deliver the chemotherapy agent cisplatin directly into treatment-resistant prostate cancer cells.
Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and Miller School of Medicine, has announced the launch of the Sylvester Survivorship and Supportive Care Institute—a dedicated survivorship institute focused on meeting the full spectrum of needs of the growing cancer survivor population in South Florida.
